On June 12, the reporter of Science and Technology Daily learned from the Second Affiliated Hospital of the Army Military Medical University (Chongqing Xinqiao Hospital) that a prospective, multicenter, double-blind, double simulation, randomized controlled clinical study led by Professor Yang Qingwu and Professor Zi Wenjie from the Neurology of the hospital - the clinical trial of early tirofiban treatment for acute non large and middle vascular occlusive stroke (RESCUE BT2 trial) has made a major breakthrough, A Chinese standard has been proposed for the treatment of acute stroke. The relevant research paper was recently published in the New England Journal of Medicine. It is understood that stroke is a major disease that poses a serious threat to global human health. Since 2005, stroke has become the first fatal and disabling disease among Chinese citizens. At present, intravenous thrombolysis is the only standard drug treatment method for acute ischemic stroke. However, the treatment time window for intravenous thrombolysis is very short. "The time window for intravenous thrombolysis treatment is only 4.5 hours after the onset of the disease." The first author of the paper, Zi Wenjie, explained that in addition to the strict Contraindication, the intravenous thrombolysis rate in China is only about 5.64%. A large number of patients who failed to receive intravenous thrombolytic therapy, especially those with non large and medium-sized vascular occlusive disabling stroke, lack effective treatment recommended by high-level Evidence-based medicine evidence. Therefore, in response to this clinical treatment dilemma, people urgently need to explore new treatment strategies. Tirofiban is a selective glycoprotein IIb/IIIa receptor inhibitor, which is effective in patients with acute coronary syndrome and is used for the treatment of heart disease. Therefore, experts speculate that it may inhibit activated platelet-mediated thrombosis during acute stroke. However, previous clinical research conclusions were inconsistent, and the scale was small or patients had mild stroke. Therefore, the efficacy of tirofiban in patients with moderate to severe ischemic stroke is not yet clear. This study was conducted in collaboration with 117 stroke centers nationwide to explore whether intravenous use of tirofiban can improve the clinical prognosis of patients with acute non large and medium vessel occlusive disabling stroke. The research results indicate that compared to oral low-dose aspirin, intravenous tirofiban treatment can significantly improve the proportion of patients with excellent functional prognosis in acute non large and medium vessel occlusive disabling stroke. This provides a new treatment method for patients who miss the golden treatment time for acute stroke, "said Zi Wenjie. The study ultimately confirmed that intravenous tirofiban treatment can significantly reduce the disability rate of patients with acute non large and medium vessel occlusion disabling stroke compared to traditional treatment methods. (Outlook New Era Network)